Literature DB >> 29270631

Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors.

Bobby Daly1, Peter B Bach1, Ray D Page2.   

Abstract

Mesh:

Year:  2018        PMID: 29270631      PMCID: PMC5838596          DOI: 10.1001/jamaoncol.2017.4473

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Authors:  Peter Q Eichacker; Charles Natanson; Robert L Danner
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

2.  Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors.

Authors:  Robert W Carlson; Joan S McClure
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

3.  Clinical Pathways: Management of Quality and Cost in Oncology Networks in the Metastatic Colorectal Cancer Setting.

Authors:  Peter G Ellis; Bert H O'Neil; Martin F Earle; Stephanie McCutcheon; Hans Benson; Melinda Krebs; Kathy Lokay; Amanda Barry
Journal:  J Oncol Pract       Date:  2017-04-05       Impact factor: 3.840

  3 in total
  2 in total

1.  "A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering.

Authors:  Jada G Hamilton; Margaux Genoff Garzon; Joy S Westerman; Elyse Shuk; Jennifer L Hay; Chasity Walters; Elena Elkin; Corinna Bertelsen; Jessica Cho; Bobby Daly; Ayca Gucalp; Andrew D Seidman; Marjorie G Zauderer; Andrew S Epstein; Mark G Kris
Journal:  J Oncol Pract       Date:  2019-01-28       Impact factor: 3.840

2.  Discordant financial conflicts of interest disclosures between clinical trial conference abstract and subsequent publication.

Authors:  Glen J Weiss; Roger B Davis
Journal:  PeerJ       Date:  2019-02-11       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.